Are you watching Pfizer (PFE) stock? With the pharmaceutical giant making headlines yet again in August 2025, investors and analysts are paying close attention to every move.
After a volatile few years post-pandemic, Pfizer’s latest earnings beat expectations, raising new questions about its future stock price, dividend sustainability, and the impact of breakthrough drug launches. News of a robust R&D pipeline, global licensing deals, and persistent cost-cutting efforts has the market buzzing.
If you’re wondering whether PFE is a buy, a hold, or a stock to avoid, this post covers the latest price trends, dividend details, recent corporate news, and what analysts expect for the rest of 2025 and beyond.
Read on for up-to-date documentation and a clear conclusion built on real-time research.
PFE Stock Price and Recent Performance
As of August 4, 2025, Pfizer (PFE) closed at $23.53 per share, reflecting a year-to-date decline of about 6.5%. Shares have continued to underperform compared to pre-pandemic highs, with a 52-week range of $20.92 to $31.54. The company’s market cap stands at approximately $143.5 billion. Trading volume remains strong, with the latest reported average hovering around 47 million shares per day.
Recent Earnings and Guidance
Pfizer released its second-quarter 2025 results on August 5. Key highlights:
- Q2 revenues were $14.7 billion, a robust 10% increase year-over-year.
- Adjusted quarterly diluted EPS reached $0.78, handily beating analyst expectations.
- Full-year guidance was reaffirmed at $61–$64 billion in revenue, with adjusted EPS guidance raised from $2.80–$3.00 to $2.90–$3.10 per share, boosted by strong demand for drugs like Vyndaqel and Eliquis.
Pfizer’s executive team emphasized continued progress on R&D, commercial execution, and operational efficiency, alongside expanded cost-saving initiatives now targeting $7.7 billion in savings by 2027.
Dividend Highlights
Pfizer continues its legacy of dividend payments. The Q3 2025 dividend was set at $0.43 per share, announced on June 25, to be paid on September 2. This marks the company’s 347th consecutive quarterly dividend, yielding an attractive 6.7%+ at current price levels—among the highest yields in Big Pharma.
Corporate and R&D News
- Pfizer received positive regulatory feedback for its latest COVID-19 vaccine adaptation in Europe in July 2025, and announced major partnerships and licensing deals internationally throughout the summer.
- Continued momentum in oncology (notably, Vepdegestrant and XTANDI combinations) and hemophilia research (HYMPAVZI™) were also featured in recent press releases.
Analyst Ratings and Price Forecasts
- Current consensus from 22 Wall Street analysts: “Moderate Buy,” with six “Strong Buy,” one “Moderate Buy,” and 14 “Hold” ratings.
- Average 12-month price target: $27.81, suggesting 14-18% potential upside from current levels.
- Some projections reach as high as $33 by late 2025 and $34 by 2030, pointing to potential long-term recovery if R&D and global growth deliver.
Conclusion
Pfizer’s stock is at a crossroads. While share price performance has lagged broader indices post-pandemic, strong earnings, a generous and reliable dividend, and an ambitious pipeline suggest long-term value. Analysts remain cautiously optimistic, highlighting the potential for a 14–40% upside as new products reach market and cost-saving measures show their effect. For income investors, PFE’s dividend is a key attraction in a turbulent market. In summary: Pfizer is a classic “blue chip” with renewed momentum. Stay tuned as the rest of 2025 unfolds—fortunes for PFE could change as quickly as the industry itself.